Diazoxide choline controlled release (Soleno Therapeutics)

二氮嗪胆碱控释剂 (Soleno Therapeutics)

Report date: 2026/04/29 20:02:18

Base Information

Drug NameDiazoxide choline controlled release (Soleno Therapeutics)
Drug Alias NameDiazoxide choline二氮嗪胆碱Vykat XrDCCRC601 +[6
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium channel agonists
TargetsPotassium channel
Therapy Area/IndicationsHyperphagiaObesityHypertriglyceridemia +[9
Global Approved IndicationsHyperphagiaPrader-Willi Syndrome
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/03/27
Country/TerritoryUnited StatesUnited KingdomEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesEssentialis Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesEssentialis Inc
Active IndicationsHyperphagiaObesityDiabetes Mellitus +[5
Inactive IndicationsHypertriglyceridemiaDyslipidemiasHyperglycemia +[4

Other Information

ATC CodeC02DA01V03AH01
Related LinksWikipediaDrugBank